tility of Non-invasive Cardiac Output Estimation in Patients Undergoing Continuous Renal Replacement Therapy and Haemodialysis

Not Applicable

Recruiting

• Conditions: kidney disease; renal replacement therapy; Renal and Urogenital - Kidney disease

• Registration Number: ACTRN12623000711617
• Lead Sponsor: Austin Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-07-04
• Last Update Posted: 10 July 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Patients will be included if the following criteria are fulfilled:
oThey are adult (patients are 18 years old or older )
oThe patient is currently undergoing either CRRT or IHD
oInformed consent can be provided by the patient or medical treatment decision maker
oAt least one arm without arteriovenous fistula and/or graft

Exclusion Criteria

Consistent with the recommendations using the ClearSight system, Patients will only be excluded if they have a clinical history of severe peripheral vascular disease or Raynaud’s disease, intubated or unable to objectively report symptoms.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
This study is looking at the tolerability of using the non invasive cardiac output monitoring device (i.e. ClearSight) in addition to usual monitoring and intermittent haemodialysis (IHD) or continuous renal replacement therapy (CRRT). The patients' tolerability of the device will be assessed by using a semi structured interview with a member of the research team. The amount of time with device tolerated by patient as a proportion of total time of dialysis session will also be used as a measure of tolerability of the device; having the device on for more than. 90% of the total treatment session will be considered tolerable. [The Clearsight device is applied to the patients up to 30minutes before their IHD or CRRT and then will continue to monitor until 30minutes after the session has finished. Each participant will only be assessed once for the entirety of the study and the monitoring is continuous <br>]